Skip to content

Study · Measured the body's own peptide · 2010

6 results

Serum thymosin beta4 levels in patients with hepatitis B virus-related liver failure.

Han T, Liu Y, Liu H, Zhu ZY, Li Y, Xiao SX, Guo Z, Zhao ZG

World journal of gastroenterology1 Feb 2010Cited by 28 (Europe PMC)

PMID20128033 (opens in a new tab)PMCIDPMC2816277 (opens in a new tab)DOI10.3748/wjg.v16.i5.625 (opens in a new tab)PepBankPUB-20128033
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Natural levels measured6

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In patients with HBV-related liver disease, serum thymosin beta4 levels were lower than in healthy controls in ACLF, CLF, CR and chronic hepatitis B.

    In plain wordsIn people with hepatitis B liver disease, the body's own thymosin beta‑4 level in blood was lower than in healthy people.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseSerum thymosin beta4 in liver disease versus healthy controls
    Study

    n = 153

    Comparator
    Healthy controls
    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    Compared with healthy controls, serum thymosin beta4 levels in ACLF, CLF, CR and chronic hepatitis B patients were significantly lower
    1 context sentence
    Summary · context
    Serum thymosin beta4 levels were measured in 30 patients with acute-on-chronic liver failure (ACLF), 31 patients with chronic liver failure (CLF), 30 patients with compensated liver cirrhosis (CR) and 32 patients with chronic hepatitis B and 30 healthy controls.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In liver failure patients, thymosin beta4 levels of non-survivors were significantly lower than those of survivors.

    In plain wordsIn people with liver failure, those who died had lower natural thymosin beta‑4 levels than those who survived.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseSerum thymosin beta4 in non-survivors versus survivors
    Study

    n = 61

    Comparator
    Survivors
    Outcome group
    Mortality · Liver

    Source sentences

    Summary
    Of the 61 liver failure patients, the thymosin beta4 levels of non-survivors were significantly lower than that of survivors (P = 0.007).
    1 context sentence
    Summary · context
    Serum thymosin beta4 levels were measured in 30 patients with acute-on-chronic liver failure (ACLF), 31 patients with chronic liver failure (CLF), 30 patients with compensated liver cirrhosis (CR) and 32 patients with chronic hepatitis B and 30 healthy controls.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    In 13 liver failure inpatients, lower initial thymosin beta4 values occurred in those who died, and greater improvement occurred in those who recovered.

    In plain wordsIn 13 people with liver failure, those who died started with lower natural thymosin beta‑4 levels and those who recovered showed greater rises.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    MixedSerial thymosin beta4 values in liver failure inpatients
    Study

    n = 13

    Outcome group
    Mortality · Liver

    Source sentences

    Summary
    The serial thymosin beta4 values were observed in 13 liver failure inpatients. Lower initial values were observed in the death. While greater improvement in thymosin beta4 value was found in those who recovered from the disease.
    1 context sentence
    Summary · context
    Serum thymosin beta4 levels were measured in 30 patients with acute-on-chronic liver failure (ACLF), 31 patients with chronic liver failure (CLF), 30 patients with compensated liver cirrhosis (CR) and 32 patients with chronic hepatitis B and 30 healthy controls.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelObservational studyOther

    Serum thymosin beta4 was markedly lower in liver failure (ACLF or CLF) than in compensated cirrhosis, and differed between CLF and ACLF.

    In plain wordsIn liver failure, the body's own thymosin beta‑4 level in blood was lower than in compensated cirrhosis.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseSerum thymosin beta4 in liver failure versus compensated cirrhosis
    Study

    n: not reported in source

    Comparator
    Compensated liver cirrhosis
    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    The levels of thymosin beta4 in liver failure (ACLF or CLF) patients were markedly lower than that in CR (P < 0.001), and a difference was also found between CLF and ACLF patients (P = 0.038).
    1 context sentence
    Summary · context
    Serum thymosin beta4 levels were measured in 30 patients with acute-on-chronic liver failure (ACLF), 31 patients with chronic liver failure (CLF), 30 patients with compensated liver cirrhosis (CR) and 32 patients with chronic hepatitis B and 30 healthy controls.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  5. 05HumanEndogenous levelObservational studyOther

    In chronic liver disease, thymosin beta4 correlated positively with albumin, choline esterase and platelet and negatively with ALT, AST, bilirubin, INR, Child-Pugh and MELD scores.

    In plain wordsIn chronic liver disease, higher natural thymosin beta‑4 levels were linked to better liver test results and lower severity scores.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    MixedCorrelation of serum thymosin beta4 with liver tests and severity scores
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    In patients with chronic liver disease, there was a positive relationship between thymosin beta4 levels and albumin, choline esterase, and platelet (P < 0.001), and negative relationship with alanine aminotransferase (P = 0.020), aspartate aminotransferase, total bilirubin, international normalized…
    1 context sentence
    Summary · context
    Serum thymosin beta4 levels were measured in 30 patients with acute-on-chronic liver failure (ACLF), 31 patients with chronic liver failure (CLF), 30 patients with compensated liver cirrhosis (CR) and 32 patients with chronic hepatitis B and 30 healthy controls.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  6. 06HumanEndogenous levelObservational studyOther

    ROC analysis identified a serum thymosin beta4 cutoff of 0.5708 microg/mL for predicting poor prognosis in all liver failure patients.

    In plain wordsIn people with liver failure, a natural thymosin beta‑4 blood level of 0.5708 microg/mL was identified as a cutoff for predicting a poor outcome.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableThymosin beta4 cutoff for predicting poor prognosis
    Study

    n: not reported in source

    Outcome group
    Mortality · Liver

    Measurements

    Prognostic cutoff
    0.5708 microg/mL
    poor prognosis in liver failure

    Source sentences

    Summary
    Receiver operating characteristics analysis identified a thymosin beta4 cutoff level of 0.5708 microg/mL for predicting poor prognosis in all liver failure patients.
    1 context sentence
    Summary · context
    Serum thymosin beta4 levels were measured in 30 patients with acute-on-chronic liver failure (ACLF), 31 patients with chronic liver failure (CLF), 30 patients with compensated liver cirrhosis (CR) and 32 patients with chronic hepatitis B and 30 healthy controls.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.